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Steroidhormonesare synthesized fromcholesterolprimarily in theadrenalglandandthegonadsandplayvital roles
in normal physiology, the control of development, differentiation, metabolic homeostasis, and reproduction. The
actions of these small lipophilic molecules are mediated by intracellular receptor proteins. It is just over 25 yr since
the first cDNA for steroid receptors were cloned, a development that led to the birth of a superfamily of ligand-
activated transcription factors: the nuclear receptors. The receptor proteins share structurally and functionally re-
lated ligand binding andDNA-binding domains but possess distinct N-terminal domains and hinge regions that are
intrinsically disordered. Since the original cloning experiments, considerable progress has beenmade in our under-
standingof the structure,mechanismsofaction, andbiologyof this important classof ligand-activated transcription
factors. In recent years, there has been interest in the structural plasticity and function of the N-terminal domain of
steroid hormone receptors and in the allosteric regulation of protein folding and function in response to hormone,
DNA response element architecture, and coregulatory protein bindingpartners. TheN-terminal domain canexist as
anensembleof conformers,havingmoreor less structure,whichprimethis regionof the receptor to rapidly respond
to changes in the intracellular environment through hormone binding and posttranslation modifications. In this
review, we address the question of receptor structure and function dynamics with particular emphasis on the
structurally flexible N-terminal domain, intra- and interdomain communications, and the allosteric regulation of
receptor action. (Endocrine Reviews 33: 271–299, 2012)
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I. Introduction
Steroid hormone receptors (SHRs) are ligand-regulatedtranscription factors that control a diverse array of
physiological processes. The importance of SHRs in the reg-
ulation of cellular and developmental processes is well es-
tablished (1–6), yet themechanismbywhich transcriptionof
target genes is controlled by steroid hormones and SHRs is
not completely understood. In recent years, studies from
many laboratories have revealed details of the mechanisms
by which SHRs modulate transcription regulation and acti-
vate cell signaling pathways (for recent reviews, see Refs.
7–11). This has resulted in the identification of molecules
withdiverse activities that regulate receptor function and the
elucidation of the role of SHRs in both normal physiological
processesandpathological conditions, includingcancer, car-
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2012 by The Endocrine Society
doi: 10.1210/er.2011-1033 Received August 1, 2011. Accepted January 25, 2012.
First Published Online March 20, 2012
Abbreviations: AF, Activation function; AR, androgen receptor; CTE, C-terminal extension;
DBD, DNA binding domain; ER, estrogen receptor; ERE, ER element; ERR, estrogen-related
receptor; GR, glucocorticoid receptor; GRE, glucocorticoid response element; HDX, hy-
drogen deuterium exchange; HRE, hormone response element; ID, intrinsically disordered;
LBD, ligand binding domain; MR, mineralocorticoid receptor; NLS, nuclear localization
signal; NMR, nuclear magnetic resonance; NTD, N-terminal domain; PPAR, peroxisome
proliferator-activated receptor; PR, progesterone receptor; RXR, retinoid X receptor; SBR,
SHR binding region; SHR, steroid hormone receptor; SRC-1, steroid receptor coactivator-1;
SRM, SHR modulator; TBP, TATA box binding protein; TFE, trifluoroethanol; TFIIF, tran-
scription factor IIF; VDR, vitamin D3 receptor.
R E V I E W
Endocrine Reviews, April 2012, 33(2):271–299 edrv.endojournals.org 271
diovascular disease, and several other disorders (12–19).
However, despite remarkable progress, the mechanisms by
which SHRs function in a tissue-specific manner remains
unclear. To more fully understand how SHRs function as
transcription factors, it is therefore necessary to know how
these receptorproteins are activatedbyhormoneandbind to
specific DNA sequences in the regulatory regions of target
genes to either up- or down-regulate the rate of transcrip-
tional initiation by RNA Pol II. Identification of the specific
factorsandmolecularmechanismsthatcontributetothenor-
mal actions andaberrant pathological effects of SHRs is crit-
ical for the development of novel and potent therapeutic
agents. It isworthnoting that steroidhormones alsomediate
rapid actions through both classical SHR and membrane-
associated receptors: these mechanisms have been discussed
in a number of excellent reviews (20–23) and will not be
specifically discussed here.
SHRs are part of a large superfamily of nuclear receptors
that share structural and functional properties (24, 25). The
cloning of the cDNA for different SHRs has greatly facili-
tated themolecular understanding of their actions as well as
receptor protein structure and function (26–33). In animals,
the main classes of steroid hormones are progestins (C22
steroids), corticosteroids (C21), androgens (C19), and estro-
gens (C18),whereasecdysone (C27), themoultinghormone,
is found in insects. Relatedmolecules that also act as ligands
formembers of the nuclear receptor superfamily include bile
acids and the sterol, vitamin D3. On the basis of amino acid
sequence homology and DNA binding specificity, the clas-
sical SHRs are found in subfamily III, which includes estro-
genreceptors (ER)and (NR3A1andA2respectively); the
estrogen-related receptors (ERR),, and (NR3B1-3); the
glucocorticoid receptor (GR; NR3C1); the mineralocorti-
coid receptor (MR;NR3C2); the progesterone receptor (PR;
NR3C3);andthereceptor forandrogens (AR;NR3C4) (25).
The receptors for vitamin D3 (VDR; NR1I1) and ecdysone
(NR1H1) are found in subfamily I and act has heterodimers
with retinoidX receptors (RXR),, or (NR2B1-3) or the
insect homolog ultraspiracle, respectively.
It is well established that transcriptional activation of
genes involves the regulated assembly of multiprotein com-
plexes on enhancers and promoters (34–36). However, de-
spiteanexponentially increasingnumberof reportedcoregu-
latoryproteinbindingpartners for SHRsand themappingof
receptor interacting domains within these proteins, the
mechanisms by which SHRs function remains an area of
important investigation. Furthermore, observations from
bothbasic biochemical analysis and recent cell-based studies
led to the inescapable conclusion that in cells, SHRs behave
very dynamically, showing rapid and reversible interactions
with partner proteins, together with chromatin and DNA
(Fig. 1) (37–41). The coupling of the functional and struc-
tural dynamics of SHRswith differences in the local concen-
trationsofpotential coregulatoryproteins is likely toresult in
receptors bringing differing sets of binding partners together
in response to agonist or antagonist ligands, such that an
agonist in one cell type can be an antagonist in another cell
type (42–45). Binding of agonistic or antagonistic ligands
leads to different allosteric changes in SHRs, making them
competent to exert positive or negative effects on the expres-
sion of target genes by different mechanisms. The result is
SHR-mediated modulation of specific responses in different
tissuesdependingon thephysiological andgenetic contextof
the cell (46–48).
Although some of these complex behaviors have been
explained by identifying cell-specific binding partners for
SHRs, it is as yet unclear whether other dynamic consid-
erations must be taken into account while defining the
underlying mechanisms, especially given the ubiquitous
nature of a large number of known coregulatory proteins.
We propose that the often disparate effects of selective
ligand modulators of SHR function, the many and varied
nonconsensus DNA response elements for SHRs, and the
effects of proteins that bind reversibly to various sites of
SHRs can be explained by the intra- and interdomain cou-
pling and structural dynamicswithin the receptor protein.
Although conformational stability of most proteins deter-
mines their biological function, it has been proposed that
the structural plasticity of the SHR proteins can explain
much about their observed behaviors (49–51). The good
and bad effects of steroids on physiology, pathophysiol-
ogy, and in therapeutic use are well documented.We con-
tend that understanding the differential effects of ligands,
response element sequences, and various protein binding
partners on the dynamic structure of SHRs will provide
essential knowledge for those seeking to design specific
steroidal (and nonsteroidal) selective SHR modulators
(SRMs), which minimize adverse side effects.
A functionally competent structure canbeachievedby the
SHRproteinthroughdifferentregionsof thereceptorrapidly
and reversibly adopting various conformations, controlled
by ligand andDNAbinding. This in turnmay help to create
protein surfaces that are readily available for selective bind-
ing to coregulatory proteins, resulting in SHR-mediated
transcriptional regulation of target genes (Fig. 1). How and
under what conditions such surfaces are created to include
or exclude coregulatory proteins in a promoter- and cell-
specificmanner is an open question. The answermay in part
lie with the dynamic structure of SHRs combined with allo-
stericregulationmediatedthroughinter-and/or intradomain
cross talk, which can be influenced by hormone binding,
DNAarchitecture, and the binding of coregulatory proteins.
In this review article, we discuss the properties of the SHRs
thatallowthisdiscriminatoryaction,which iscritical toSHR
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transduction of different signals. It is timely in light of recent
advances in ourunderstandingof SHRprotein structure and
the growing interest in targeting regions of the receptor dis-
tinct from the ligand binding pocket, with small molecule
modulators that may ultimately lead to a new portfolio of
tailored therapeutic treatments for hormone-dependent
diseases.
II. Functional and Structural Organization of
Steroid Hormone Receptors
From early biochemical studies with purified receptor pro-
teins, it was deduced that SHRs would consist of discrete
regions important for hormone and
DNA binding (52). Limited proteolysis
and antibody binding identified a third
distinct region, termed the “immunoac-
tive” domain (53, 54). The cloning of the
ER and GR cDNA in the mid-1980s
andsubsequentdeletionmapping studies
refined this domainorganization into the
picture we have today (Fig. 2A). SHRs
are modular proteins that consist of a
highly variable N-terminal domain
(NTD; also called A/B domain); a 66-
amino acid core DNA binding domain
(DBD; orC domain); a flexible hinge do-
mainof40to60aminoacids(Ddomain);
a ligand binding domain (LBD) of about
265aminoacids (Edomain); and in some
receptors a variable stretch of amino ac-
ids at the very C terminus referred to as
the F domain (Fig. 2A) (24). Two activa-
tion domains, termed AF1 and AF2, are
located within the NTD and LBD, re-
spectively, and are responsible for medi-
ating the transcriptional activity of
SHRs.The twoAFcanact in an indepen-
dentmanner, althoughusually full recep-
tor activity requires synergistic coopera-
tion between AF1 and AF2. This
cooperativity can be mediated by direct
receptorN/C-terminal interactionsor the
bindingof coregulatoryproteins toeither
activation function separately or simul-
taneously to both AF1 and AF2.
A. Ligand binding domain (LBD) (AF2)
1. Hormone binding
In the absence of hormone, SHRsare
present in a heterocomplex with heat
shock proteins and immunophilins
(Fig. 1). This complex has been particularly well studied
for the GR and consists of a dimer of hsp90, together with
one copy of hsp70, p23, and the immunophilins FKBP51
and -52; the latter have been proposed to link SHRs to the
motor protein dynein and the microtubule retrograde
transport network (reviewed in Refs. 55 and 56). The
binding site for hsp90 on the GR has been mapped to a
seven-amino acid sequence at the N-terminal end of the
LBD (residues 529 to 535 for human GR), but the exact
sequence of amino acids was found not to be critical for
this interaction (57). Importantly, thebindingof thehsp90
heterocomplex was essential for maintaining the GR in a
Figure 1.
Figure 1. General dynamics and mechanism of SHR action. SHR action is spatially, temporally,
and structurally highly dynamic. In the absence of hormone, the receptor is complexed with
co-chaperone molecules (green) in the cytoplasm. The NTD/AF1 exists in an ID conformation,
compared with the well-ordered DBD and LBD. Factors affecting disorder-order transition of
the SHR AF1/NTD are illustrated. The binding of hormone (I) causes rearrangement of regions
in the LBD (helix 12, AF2), and this leads to translocation to the nucleus and binding to DNA
response elements and coregulatory proteins (blue) (II). Under the influence of factors shown,
NTD/AF1 undergoes disorder-order transition, resulting in the folding of NTD/AF1. In this
conformation, AF1/NTD surfaces are well suited for the interaction with specific coactivators,
binding of which further influences the conformation of NTD/AF1 and facilitates the assembly
of the transcription initiation complex (blue) in a promoter-specific manner (III). The binding of
DNA and/or coregulatory proteins may allosterically regulate ligand binding, which could lead
to formation of SHR-transcription complexes (IV). The formation of transcriptionally
competent complexes by the DNA-bound SHR (III) must be readily reversible, and the co-
chaperone complex (green) may aid in dissociating the SHR-chromatin complex, recycling of
the receptor protein to the cytoplasm, and stabilization of the ID NTD/AF1 (V). The SHR is also
subject to posttranslational modifications, such as phosphorylation (P), which are likely to
fine-tune the allosteric regulation of receptor structure and function.
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state primed to bind hormone because reducing levels of
hsp90 in yeast cells inhibited receptor action (58). In ad-
dition to a role in hormone binding, interactions with
hsp90 are important for cycling of SHRs on DNA/chro-
matin and for receptor turnover (56, 59) (Fig. 1).
The primary role of the LBD is to bind specific steroid
ligands,which becomeburied in the hydrophobic interior.
Selectivity of different hormones is based upon the size of
the ligand binding pocket and interactions between spe-
cific amino acids and the A and D rings of the steroid
Figure 2.
A
B C
D
Figure 2. SHR domain structure and function. A, Schematic representation of the domain organization of SHRs, showing the LBD and DBD and the
structurally distinct NTD. Regions of the receptor protein important for ligand binding, DNA binding, dimerization, and transactivation are indicated below
the protein. The position of the NLS and the CTE of the core DBD are also shown. Sites of potential posttranslational modification are indicated above the
protein: including, acetylation (Ac), phosphorylation (P), methylation (Me) and sumoylation (SUMO-1; small ubiquitin-like modifier 1). B, Crystal structures
for the LBD of the ER bound with agonist (estradiol) (pdb 1ERE) or a selective ER modulator (4-hydroxhtamoxifen) (pdb 3ERT). The ligand binding pocket
is indicated, as is the position of helices 1 and 12 and the AF2 surface (blue oval). C, Structures of the ER-DBD (ER: pdb 1HCQ), which binds to a near
palindromic DNA sequence as a homodimer. The presences of the P- and D-box amino acid residues are indicated. D, The crystal structure for PPAR-
RXR heterodimer complex (pdp 3E00) on a direct repeat response element, with the half-sites separated by 1 bp. The PPAR structure is in yellow, and
RXR is in blue; the hinge region of PPAR is indicated.
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molecule (reviewed inRef. 60). Fromanalysis of the amino
acid sequences of SHR-like proteins from different organ-
isms, including invertebrates such as molluscs and anne-
lids, it has been proposed that the ancestral gene for SHRs
was ER-like and bound estrogens (reviewed in Ref. 61).
The binding of hormone has dramatic consequences
for individual receptor structure-function relation-
ships. Structures of the LBD for each class of SHR
bound to either agonists or antagonist are available.
The LBD is made up of 11 -helices and a variable
number of -strands; for example, the ER-LBD has 11
helices and two -strands (Fig. 2B) (reviewed in Ref.
60). The agonist-bound receptors share a globular
folded structure that has been described as a three-layer
helical sandwich, with the hormone buried within the
ligand binding pocket and sealed in by the conforma-
tional change in helix 12 (note that convention names the
helices 1 to 12 after the first structures solved; in the SHR
subfamily, helix 2 is absent or disordered). The reorien-
tation of helix 12 in response to hormone binding, to-
getherwith residues in helices 3, 4, and 5make up theAF2
surface (62–64). This surface pocket has a hydrophobic
interior and typically binds coactivator proteins contain-
ing the peptide motif LxxLL (where L is leucine and x is
any amino acid) that forms a -helix, which buries the
leucine residues within the groove (62). In addition to the
hydrophobic surface, the LxxLL helix is orientated by a
lysine residue in helix 4 and a glutamic acid in helix 12,
which together form a “charge clamp” (63, 65–67).
Extensive analysis of ER and ER LBD revealed the
importance of residues outside the ligand binding pocket
that contributed to receptor-specific ligand interactions
and allosteric communication with the coactivator bind-
ing surface (64). In particular, the position of helix 11was
implicated in ER subtype-selective agonist, partial ago-
nist, or antagonist responses to a particular ligand. An
allosteric network linking the ligand binding pocket and
the AF2 surface was also elegantly demonstrated through
a mutation screen with the GR. A number of mutations
were identified that reduced the requirement for hsp90 in
hormone binding by the receptor: two of the residues,
tyrosine 598 (numbering for human GR) in helices 5–6
and methionine 752 (helix 12) contribute to the AF2 sur-
face,whereas a third residue,methionine604 (helices5–6)
is part of the ligand binding pocket, which provides a
structural basis for the allosteric regulation of ligand and
coregulatory protein binding to the LBD (68). This study
also revealed a further role for hsp90 in connecting this
allosteric network.
The structure of the LBD of ER and AR bound to an-
tagonists or SRMs have also been solved (e.g., Fig. 2B). In
these cases, it is interesting that the overall fold of the LBD
remains similar to that of the agonist-bound receptor, but
there are changes within the ligand binding pocket or in
the position or flexibility of helix 12. In the case of the ER
SRMs, tamoxifen (Fig. 2B) and raloxifene, displacement
of helix 12 prevents coregulatory proteins binding to the
AF2 surface (60, 69, 70).The agonist activity of tamoxifen
in certain cells has been shown to depend on AF1 because
removal of the NTD of the receptor abrogates the activa-
tion of a target gene by this ligand (71–73).
Interestingly, other surfaces on the AR-LBD have been
shown to bind small molecules that interfered with the
binding of coregulatory proteins to the AF2 site (74). It is
tempting to speculate that this site, termed “BF3,” is an
auxiliary protein-protein binding site or that it could be
exploited as an allosteric drug binding surface.
2. Dimerization interfaces
Sequences within the LBD have also been identified as
dimerization interfaces. ER-LBD dimerization involves
amino acids in helix 10, but the dimerization interface for
the GR-LBD comprises residues in helices 1, 3, and 5 (43,
75–77). However, whether the presence of a dimerization
site within the LBD is common to all SHRs is less clear. In
the case of the AR, this is a subject of debate, and it is
noteworthy that in the crystal structures of the AR-LBD,
only monomers were observed. A recent comparison of
the AR-LBD with the GR sequence and structure identi-
fied residues in helices 1, 3, and 5 as a potential dimeriza-
tion interface (78). The involvement of different regions of
the LBD in dimerization suggests that this interaction
could be differentially regulated allosterically by hormone
binding, which in turn could lead to cell- or gene-selective
responses through the exposure of different surfaces for
coregulatory protein binding.
3. N/C-terminal interactions
Interestingly, whereas other SHRs interact with coacti-
vator proteins via LxxLL motifs, which bind in the hy-
drophobic groove of AF2, the AR-LBD preferentially
binds the AR-NTD and coactivators with more bulky hy-
drophobic residues in the sequence F/WxxLF/W/Y (65–
67, 79–81). This AR-N/C terminal interaction results in
stabilization of the receptor protein, a reduction in the
dissociationof hormone and selective gene activation (82–
84). There is also growing evidence that N/C-terminal do-
main interactions occur for other SHRs, for example ER
(85, 86), PR (87, 88), and the MR (89).
The structural basis for the AR-LBD/AF2 binding pref-
erence for bulky hydrophobic aromatic residues over leu-
cine has been reported (65–67). X-ray crystallography
studies showed that the AR-NTD FxxLF motif forms a
charge clampwith glutamic acid 897 in helix 12 and lysine
Endocrine Reviews, April 2012, 33(2):271–299 edrv.endojournals.org 275
720 at the C-terminal end of helix 3, and the bulky hy-
drophobic side chains fit better into the surface pocket on
theLBD. In contrast, anLxxLLmotif peptide fails tomake
hydrogen bond contacts with the glutamic acid residue in
helix 12 and makes fewer hydrophobic contacts with the
surface of the LBD (65–67).
It can be concluded from the above studies that the
binding of hormone acts as an allosteric switch to regulate
SHR-DNA and SHR-protein interactions, including in-
terdomain interactions and/or dimerization.
B. Hinge region
The binding of steroid leads to exposure of the nuclear
localization signal (RKxK/RK), within the hinge domain,
and translocation of the receptor-steroid complex into the
nucleus and subsequent DNA binding (Fig. 1). The hinge
region is a 40- to 60-residue linker sequence between the
DBD and the LBD, which shows little amino acid homol-
ogybetweendifferent SHRs.Thehinge regioncontains the
C-terminal extension (CTE) of the DBD, the nuclear lo-
calization signal (NLS), and sites for posttranslational
modifications (Fig. 2A).
The CTE is defined as the sequence immediately C-ter-
minal of the conserved second zinc finger of the coreDBD.
In the case of nonsteroid receptors, for example in the
VDR and the thyroid hormone receptor  (NR1A2,), the
CTE forms an -helix and is important for het-
erodimerization with RXR and minor groove DNA con-
tacts (reviewed in Ref. 90). In the original structures of the
GR and ER and subsequently the AR DBD, the CTE ap-
peared disordered, although mutational studies high-
lighted a role in DNA binding (91–94). Interestingly, re-
cent structural analysis of a number of GR-DBD-DNA
complexes observed a helical conformation for the CTE
(95). Electron densities were also observed for the first
seven to eight residues of the PR-CTE, which revealed
interactions with both the minor groove and the core PR-
DBD (96, 97). Mutational analysis demonstrated that the
PR-CTE was necessary for recognizing nucleotides flank-
ing the DNA response element (96). More recently, the
hinge region of the PR was found to regulate the response
of the receptor on different promoters. This involved cy-
toplasmic/nuclear shuttling and retention in response to
acetylation of lysines in the NLS and phosphorylation of
serines in the NTD (98).
Structural and functional analysis of the AR-hinge re-
gion (residues 629 to 634) showed that theNLS interacted
with the armadillo repeats 2, 3, and 4 of the NLS receptor
protein -importin (99). An extended receptor peptide
(amino acids 617 to 634) adopted a -turn-like structure
when bound to -importin, which was unique to the AR
NLS (99). Recentmutational analysis of this basicmotif in
the AR demonstrated a number of functional interrela-
tionships, including nuclear localization, DNA binding,
intranuclear dynamics, and transcriptional activity (100).
The lysines in this motif are also subject to acetylation
(101–103) and methylation (104).
Collectively, the above-mentioned studies strongly sug-
gest that the CTE can adopt different conformations de-
pending upon whether the receptor is bound to DNA,
protein partners, or free in solution (99, 105, 106). Fur-
thermore, because the CTE itself appears to be an intrin-
sically disordered (ID) region, it suggests the possibility
that CTE interactions are involved in mediating allosteric
coupling with the NTD and LBD (discussed in Sections
V.B.2. and V.I).
C. DNA binding domain (DBD)
On the basis of amino acid sequence homology and
DNA binding specificity, SHRs can be classified as mem-
bers of theERsubfamily (ER,, andERR,, and) and
the GR subfamily (GR, MR, PR, and AR) (25). The core
DBD of SHRs consists of approximately 66 amino acids
and involves the coordination of two zinc ions by eight
cysteine residues (90, 107). SHRs typically bind in vitro to
palindromic or palindromic-like DNA sequences as ho-
modimers. The consensus sequences for ER have the half-
site 5-AGGTCA-3, and for GR, PR, MR, and AR the
half-site is 5-AGAACA-3; each half-site is separated by
a three-nucleotide spacer, completing the 15-bp receptor
response element (90, 107). Early pioneering mutagenesis
and “domain swapping” experiments identified a se-
quence of three amino acids, termed the P-box, within the
first zinc-finger module as being important for DNA re-
sponse element recognition and binding. In the case of the
ER, these residues are glutamic acid, glycine, and alanine,
whereas the corresponding amino acids in the GR sub-
family are glycine, serine, and valine (108, 109). In the
secondzinc-fingermodule, a five-aminoacid sequence, the
D-box, was found tomediate dimerization of the receptor
on DNA (90, 107).
The first SHR structures to be solvedwere theGR-DBD
by nuclear magnetic resonance (NMR) spectroscopy (91)
and the solution and crystal structures of the ER-DBD
(92, 93). These studies revealed that the DBD folded into
a compact globular structure containing two principal
-helices perpendicular to each. The recognition helix fit-
ted into themajor grooveofDNAandcontained theP-box
residues (Fig. 2C), whichmade direct andwater-mediated
hydrogen bonds with the nucleotide sequence. In addi-
tion, there are a number of interactions between amino
acid side chains and the phosphate backbone of the
DNA. The second helix acts to stabilize the recognition
helix in place. The five amino acids of the D-box form
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an exposed loop structure (Fig. 2C) and mediate the
“head-to-head” binding of the receptor monomers on
the DNA response element.
Although the overall folding of the DBD is very similar
for all receptors studied, thereare somedifferences that are
thought to be functionally important. For example, the
structure of the AR-DBD forms a more closely packed
dimerization interface than that observed for the GR-
DBD, and it has been proposed that this, in part, is the
basis for AR binding to androgen response elements, a
subset ofDNA response elements that are selective for this
receptor (94). Furthermore, whereas the main determi-
nants for DNA binding reside within the P-box residues,
it has become apparent that the region immediately adja-
cent to the DBD, termed the CTE, also has a role to play
in stabilizing DNA binding and/or response element se-
lection by SHRs through contacts with the minor groove
of DNA (96, 110).
A recent structural analysis has highlighted the alloste-
ric properties of DNA binding. Receptor binding sites as-
sociated with glucocorticoid-regulated genes were shown
to influence the composition of coregulatory complexes
recruited by the GR (95). The binding of the GR-DBD to
different response elements was found to be asymmetric,
and a region of the DBD, the “lever arm,” was found to
adopt different conformations depending on the DNA ar-
chitecture (95). The lever arm consists of the amino acids
Glu450-Gly-Gln-His-Asn-Tyr455, which are conserved in
the PR- and MR-DBD, but shows three and four amino
acid changes in the AR and ER, respectively. The histidine
at position 453 adopted one of two possible conforma-
tions in the DBD dimer: in the upstream monomer the
histidine was packed in the DBD core, whereas for the
downstream monomer the residue was “flipped out” and
conformationally flexible (95). The glutamic acid and the
tyrosine participated in contacting DNA; both these res-
idues are found in AR,MR, and PR, but only the tyrosine
is found at the same position in the ER/. It remains to
be investigated more fully to determine whether the lever
arm is a common property of the SHR-DBD and to de-
termine the mechanism(s) of allosteric control to the GR-
AF1 or -AF2 activities. These studies reveal the structural
dynamics imparted by DNA recognition and binding and
highlight the potential regulatory role of different DNA
sequences or binding partners, which could lead to cell or
promoter selective SHR function.
Recent advances in genome-wide analysis of SHR-regu-
latedgeneshavedramatically increasedourability to identify
hormone-regulated gene networks and have allowed for the
identificationof SHRbinding regions (SBRs) throughout the
genome. The outcome of these studies has been the reve-
lation that receptor binding sites can have degenerate se-
quences and different architecture of half-sites (palin-
dromes, inverted palindromes, and repeats), although
typically a high-affinity half-site matching the consensus
sequence is always present (111–117). The other out-
comes fromthese chromatin immunoprecipitation (ChIP),
or ChIP-seq, studies are the observations that: 1) there is
a high preponderance of other transcription factor bind-
ing motifs associated with receptor response elements
(e.g., Foxo A1, ETS1, GATA2); and 2) in some cases the
SBR can be more than 10 kb away from the transcription
start site of the regulated gene (111–113, 116, 117), al-
though other studies reported SBR within 1.5 kb of the
transcription start site (112, 115). Of particular interest
was the comparison of genomic binding sites for the GR
across four mammalian species, which revealed that se-
quence conservation for individual sites was greater be-
tween species than for receptor binding sites within the
same species (116, 118). The latter observation empha-
sizes the potential importance ofDNAarchitecture of SBR
for gene selective regulation by the GR.
D. N-terminal domain (NTD) (AF1)
TheNTDof SHRs is highly variable in both amino acid
sequence and length, with theMR, PR-B isoform, and AR
having NTD of greater than 500 amino acids, the largest
of any members of the nuclear receptor superfamily (re-
viewed in Ref. 50). In contrast to the DBD and LBD, there
is little amino acid sequence homology between the dif-
ferent classes of SHR-NTD. However, comparison of the
primary sequence for a given receptor across different spe-
cies does reveal regions of conserved residues (50). Such
conserved sequences often colocalize with regions delin-
eatedasnecessary for receptor-dependent gene regulation,
which in turn are involved in protein-protein interactions
(49, 50). Deletion of the LBD of SHRs results in a protein
that is constitutively active in reporter gene assays, and
thus the function of AF1 has been described as hormone-
independent (see Ref. 50 and references therein). A signif-
icantnumberof coregulatoryproteinshavebeen identified
binding to AF1, including chromatin modifying enzymes,
basal transcription factors, coactivators, and corepressors
(reviewed in Ref. 50). In some cases, the same binding
partner has been described as interacting with both AF1
and AF2 through distinct receptor-interacting domains
(119, 120).
Deletion studies have defined the AF1 of the ER (72,
121) and GR (122) to 100 and 200 amino acid regions of
the respective NTD. The location and nature of the GR-
AF1 was further refined to a 58-residue core domain
(amino acids 187 to 244; GR-AF1core) (123). This
AF1core domain retained 60 to 70% of the activity of the
full-length AF1. Point mutational studies revealed an im-
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portant role for hydrophobic amino acids in AF1core ac-
tivity (124, 125), whereas mutations that reduced the
overall acidity of the AF1 domain led to progressive im-
pairment of transactivation (126). It was speculated that
these residueswere important structurally and defined the
solvent exposed surface of the transactivation domain. It
is significant, therefore, that mutating key glutamic acid,
phenylalanine, or tryptophan residues in the correspond-
ing enh2 domain (amino acids 108 to 317) of the rat GR
impaired transactivation activity, but not the ability to
repress transcription through protein-protein interactions
with the transcription factor activator protein 1 (127).
Although the term “AF1” is used to describe the trans-
activation function of the SHR-NTD in some receptors,
the activity is highly modular and can map to multiple
sequences within the NTD. Deletion of the AR-NTD re-
sults in a transcriptionally weak protein, providing evi-
dence for the main transactivation function being lo-
cated within the NTD (128, 129). The AR-AF1 is
modular in nature, and regions important for transac-
tivation have been characterized by deletion analysis
(128, 129), by the use of fusion proteins (129), and by
point mutation (130, 131). These studies identified two
overlapping regions, amino acids 101 to 370 and 360 to
485, as being critical for receptor-dependent transacti-
vation, and highly conserved hydrophobic amino acids
within this region have been shown to be important for
activity and protein-protein interactions.
Similarly, multiple regions have been identified within
the PR-NTD (132) and MR-NTD (133–135) that, when
deleted, impaired receptor-dependent transactivation.
TheAF1domainor related SHR-NTDactivities havebeen
shown to function inavarietyofmammalian cell types and
in the budding yeast Saccharomyces cerevisae and when
fused with a heterologous DNA binding domain. A strik-
ing exception to the later observation is the isolated PR-
AF1 domain, which requires the PR-DBD to be function-
ally active, emphasizing the importance of intradomain
communication (132).When taken together, these studies
illustrate that different surfaces, evenwithin a single SHR-
NTD, can be involved in activation, or indeed repression,
of transcription. Furthermore, the strength of the respec-
tive SHR-NTD in activating transcription is also variable.
A clear correlation between AF1 activity (and inversely
AF2 activity) and the length of the NTD has been dem-
onstrated using GalDBD-NTD fusion proteins, with the
longer AR- and PR-NTD showing the highest activity in a
reporter gene assay (66).
III. Structural Analysis of Full-Length
Nuclear Receptors
Significant insight has been provided by x-ray crystallog-
raphy and/or NMR spectroscopy of the isolated DBD and
LBD. However, the presence of significant regions of in-
trinsic disorder (Section V) and overall protein size have
hampered attempts to determine the three-dimensional
structure of a full-length SHR.
In contrast, a recent x-ray structure of a complex con-
taining the full-length peroxisome proliferator-activated
receptor (PPAR)  and RXR nonsteroid nuclear recep-
tors has been published (105) (Fig. 2D), whereas solution
studies, using small angle x-rays and fluorescence reso-
nance transfer, have described the “shape” of a number of
nonsteroid nuclear receptor complexes (136). Isothermal
calorimetry andhydrogendeuteriumexchange (HDX) ex-
periments have elegantly revealed interdomain and inter-
receptor communication for the thyroid hormone recep-
tor (137) and the VDR (138) heterodimer complexes with
RXR, respectively.
In the crystal structure of PPAR and RXR bound to
a DR1 DNA response element (5-AGGTCAnAGGTCA-
3), the complex is asymmetrical, and the overall confor-
mation of the individual LBD and DBD were remarkably
similar to the structures of the isolated domains and those
described above for SHRs (Fig. 2D) (105). In the crystal
complex, the PPARmonomer adopted a “closed” confor-
mation with extensive interactions between the LBD and
the PPAR-DBD and the RXR-LBD, Hinge, and DBD
(105). In contrast, theRXRmonomer had an “open” con-
formation with the hinge region extended, creating a sur-
face for PPAR binding. The hinge region of the PPAR also
made contact with the DNA and contained two -helices,
whereas the RXR hinge region was more flexible and
lacked secondary structure (Fig. 2D) (105). The functional
importance of the interaction of the PPAR-LBD with the
DBD was supported by the introduction of a F347A mu-
tation.This residue is not directly in contactwith either the
ligand binding pocket or the AF2 region, but impaired
DNA binding and transcriptional activation (105). The
NTD of both receptors, although relatively short at 110
and 134 amino acids, respectively, were not observed in
the crystal structure of the complex and were highly dy-
namic as determined by HDX experiments.
However, these different conformations of the hinge
region or the closed complex of PPAR were not observed
in the solution structures of a number of class II receptors
bound with RXR to different response elements (136).
Although these studies lack atomic resolution, they re-
solved as a homogenous complex and generally all show
the receptors as an elongated shape in an open conforma-
tion, with the hinge regions in extended conformations,
permitting the ordering of the LBD over the 5 half-site of
theDNAelement (136). Furthermore, the coactivatorpro-
tein Med1 bound with a 1:1 stoichiometry with the re-
ceptor heterodimer complex and only bound to the RXR
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partner (136). This is in contrast to other studies that sug-
gest binding of coregulatory protein fragments to both
receptors in similar receptor complexes, although binding
to one partner could be modulated by the DNA response
element (138).
Zhang et al. (138) have used HDX to investigate the
consequences for receptor conformation of ligand bind-
ing, DNA response element binding, and coregulatory
protein interactionsusing theVDR-RXRheterocomplex
as a model. Binding of either ligand alone caused changes
in HDXwithin the cognate receptor LBD and the LBD of
the receptor partner. As might be expected, a number of
these changesmapped to regions of the receptors involved
in heterodimerization (138). However, there were also
perturbations at distant sites; for example, 1,25-vitamin
D3 binding caused changes in helix 3 of the RXR partner,
suggesting allosteric interreceptor communication. Most
strikingwas the destabilization of the VDR-DBDby bind-
ing of either 1,25-vitamin D3 or 9-cis-retnoic acid (138).
DNA response element recognition and binding also re-
sulted in changes in HDX of both receptors; there was
strong protection from solvent exchange for the VDR-
DBD/CTE, consistent with more contacts with the DNA
(138). DNA binding, and significantly the architecture of
the DNA response element, also led to changes in the LBD
of both receptors: the regions affected were the dimeriza-
tion interface andAF2 surface. A 1:1 complexwas formed
between a fragment of the steroid receptor coactivator-1
(SRC-1) (NCoA1) and VDR-RXR: with VDR binding to
the NR3 box and RXR to NR1 box (p160 family of co-
activators, NCoA1, 2, and 3, have three LxxLL motifs
termed NR box 1 to 3). The nature of the DNA response
element was shown to alter the conformation of the AF2
regions such that there was a reduction in VDR and en-
hancement of RXR interactions with SRC-1 (138).
Taken together, the structural analysis of full-length or
two-domain receptor proteins, in complex with different
DNAresponse elements, illustrates the complexity ofmul-
tiple inter/intradomain interactions and the possible
mechanismsof allosteric regulation impartedupon ligand,
DNA, or coregulatory protein binding. Furthermore, the
above-mentioned structural studies have highlighted the
growing importance of the hinge domain in regulating
receptor conformation and complex “shape.” In light of
these studies with class II nuclear receptors, which form
heterodimeric complexeswithRXR, itwill bevital to solve
the structures for SHR complexes containing at least two
domains. Because these receptors bind topalindromic-like
DNA sequences as homodimers, such studies are required
to determine what conformation(s) are adopted by the
hinge regions of each monomer and to identify the intra/
interdomain communications, which would highlight the
potential mechanisms of allosteric regulation in response
to hormone and DNA binding.
IV. Steroid Hormone Receptors Function in a
Ligand-, Cell-, and Promoter-Specific Manner
Allosteric regulation is a property that arises from the
modular structureof SHRs.The consequenceof this is that
multiple surfaces can engage in protein-protein interac-
tions (i.e., AF1, AF2, lever arm, and the CTE), and acces-
sibilityof these sites is regulatedby thebindingofhormone
and the DNA architecture. Thus, the means of gene- and
tissue-specific regulation reside within a single transcrip-
tion factor. The cellular context (SHR protein levels and
coregulatory protein levels) and chromatin environment
will also influence the SHR transcriptional activity, but in
this review we emphasize the features within the receptor
protein that underpin this regulation.
A. Selective utilization of AF1 and AF2: cell
culture studies
Initial studies mapping the functional domains of the
ER led to the observation of cell and promoter (gene)
discriminating functions for the AF1 and AF2 surfaces.
Strikingly, using receptor constructs lacking the NTD or
the LBD, it has been shown that AF1 and AF2 function in
a cell type-specific manner. For example, AF1 was active
in CEF (chicken embryonic fibroblast) cells, HepG2 liver
cells, and thebreast cancer cell linesT47DandMCF-7,but
not in HeLa cells (42, 73, 139). Furthermore, dependence
onAF1 appeared to correlate with themore differentiated
breast and prostate cancer cell lines, whereas AF2-depen-
dent activity showed the opposite trend (73).
The activation functions of ER also showed promoter
selectivity, with AF2 being active on more complex pro-
moters and having the ability to synergize with both AF1
and other transcription factors (71, 139). In contrast, in
CEF permissible cells, AF dependence did not distinguish
between “complex” and “simple” (response element 
TATA-box) promoters and failed to act cooperatively
with other transcription factors (139).
Evidence for differential utilization of the GR-AF1
and -AF2 domains comes from studies using the human
osteosarcoma cell line U2OS expressingwild-type or vari-
ants of the GR with mutations in either AF1 (E219K/
F220L/W234R) or AF2 (E773R) (95, 140, 141). After
expression profiling to identify GR-regulated genes in
U20S cells, a panel of nine genes were selected for inves-
tigation. On the basis of expression in response to the
synthetic glucocorticoid dexamethasone, the genes were
classified as: AF1-dependent (IGFBP); AF2-dependent
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(PDGF, SGK, ladinin1, SDPR,MSK2, IRF8, andGILZ);
AF1- andAF2-dependent (hIAP); or intriguingly, immune
to mutation in either AF1 or AF2 (I6PK) (140, 141).
More recently, differential phosphorylation of the hu-
man GR-AF1 at specific serine residues has been corre-
lated with gene expression. There is an increase in phos-
phorylationof theGRon serines 203, 211, and226within
the AF1 domain in response to hormone binding (142,
143). GR phosphorylated on serines 211 and 226 was
recruited, albeit with different kinetics, to receptor bind-
ing sites in theTAT, SULT andGILZ genes in response to
hormone. In contrast, the receptor phosphorylated on ser-
ine 203 was not observed at these glucocorticoid-regu-
lated genes (143).
In the case of the AR, a dependence upon the N/C-
terminal interaction was found to distinguish different
sets of AR-regulated genes, such that mutations dis-
rupting the interaction impaired transcription of PSA,
probasin, and C3(1) genes, but not slp or MMTV (83,
84). Collectively, these studies illustrate the importance
of different regions of SHRs (AF1/NTD, AF2/LBD) for
target gene expression and provide a starting point for
evaluating the mechanisms for this selectivity, which is
likely to involve specific protein-protein interactions
and posttranslational modifications.
B. Selective utilization of AF1 and AF2: in vivo studies
The above-mentioned in vitro studies have been instru-
mental in highlighting the potential for differential use of
SHRactivation functions, but compelling in vivo evidence
has only recently become available. In vivo it has been
shown that ER-AF1 was not required for vasoprotective
actions of estradiol butwas important for ER function in
reproductive tissues (144). A similar transgenic mouse
model has been used to investigate the role of ER acti-
vation functions in bone: comparing the consequences of
a complete ER gene deletion with either a deletion of the
ER-NTD(AF1) or a deletion impairing AF2 function in
ovariectomized animals treatedwith estradiol (17). ER is
necessary formaintaining bone density and structure, and
it was demonstrated that AF2 was important for both
cortical and trabecular bone; crucially the requirement for
AF1 was more tissue specific, having a role in trabecular,
but not cortical bone (17). Together, these in vivo studies
could show that AF1 activity was important for estradiol
action in the uterus, but not for the increase in liver weight
in response to hormone treatment (17, 144). The signifi-
cance of these findings lies not just in providing evidence
for tissue/cell-specific selectivity of AF1 and AF2, but also
in illustrating the possibility of therapeutically targeting
these receptor functions to achieve tissue restricted effects.
Thus, blocking ER-AF1 to treat uterine cancer should
not impact upon ER activity in maintaining cortical
bone.
The above-mentioned studies demonstrate the potential
for different SHRsurfaces tobeused in a cell- andpromoter-
specific manner. Further experiments are clearly needed to
extend these observations and to determine the molecular
mechanisms regulating the display and function of different
SHR surfaces.
V. Intrinsically Disordered Structure and
Steroid Hormone Receptor Action
The traditional view in biology is that the specific func-
tion of a given protein is determined by its unique three-
dimensional structure, the so-called “lock and key” hy-
pothesis. However, in recent years, it has become quite
evident that many biologically important proteins pos-
sess large stretches of amino acid sequences that do not
adopt a well-defined three-dimensional structure (145–
150). These unstructured proteins/protein regions have
been termed “intrinsically disordered” and exist as dy-
namic ensembles of interconverting conformers that are
capable of undergoing disorder/order transition under
specific physiological conditions (Fig. 3) (151–154).How-
ever, in contrast to structured or ordered proteins whose
conformation is relatively stable with occasional cooper-
ative conformational switches, they do not automatically
adopt a classical fully folded and well-defined functional
structure and typically undergo conformational changes
(155–159). Both random coil-like and collapsed (partially
folded or molten globule-like and premolten globule-like)
conformations with poorly packed side chains are the fea-
tures of ID proteins/regions (Fig. 3) (160, 161).
In recent years, it has become evident that eukaryotic
genomes are highly enriched in ID proteins, which appear
to promote molecular recognition (162). Based on bio-
physical and computational analyses, ID regions/domains
are prevalent in amajority of transcription factor proteins,
including the hinge and NTD of SHRs (49, 50, 163–166).
Characterization of the conformational propensities and
functionof suchnonglobular protein sequences represents
a major challenge.
A. What does it mean to be intrinsically disordered?
The complex and highly coordinated interactions of
proteins play a fundamental role in the control of cellular
physiology, where different functions can be achieved via
recognitionof specific andunique identification sequences
frequently found inside ID regions (145–150, 154). It has
been predicted that a number of signaling proteins
(65%) possess long ID regions/domains, which play a
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critical role in cell cycle control, transcriptional and trans-
lational regulation, and signal transduction; this number
is predicted to be much higher (75%) for cancer-asso-
ciated proteins (165, 167). The significance of such ID
domains/regions in signaling molecules is that their con-
formational flexibility creates large interaction surfaces
that allow macromolecular interactions with high speci-
ficity and low affinity through coupled binding and fold-
ing, an important property of signaling proteins promot-
ing molecular recognition that provide specific, but
reversible, interactions with target molecules (151–154).
The function-associated conformational changes and dis-
order-to-order transitions may be brought about by alter-
ations in environmental or cellular conditions. The ID na-
ture of proteins also provides a possible mechanism for
their actions to be regulated through posttranslational
modifications, such as kinase-dependent phosphorylation
(153, 180). Furthermore, sites of other posttranslational
modifications such as acetylation, hydroxylation, ubiq-
uitination,methylation, and sites of regulatoryproteolytic
attack are frequently associated with ID regions (168).
The functional importance of conformational changes
and disorder-to-order transitions in ID proteins stems
from a large decrease in conformation entropy, which in
turn can uncouple specificity from binding strength. This
enables highly specific interactions to be easily reversible,
which is beneficial for proteins involved in sig-
naling and transcriptional regulation.
B. Coupled folding and binding of the steroid
hormone receptor NTD
The primary amino acid sequences of the
NTD of the SHR, which contain AF1, are
much less conserved than are DBD and LBD
regions (50, 60, 169–171). Despite having
poor sequence homology, these regions are
highly enriched in charged amino acids and
have low hydrophobicity, which is a signature
for ID (49, 50). Studies from several laborato-
ries have confirmed the ID nature of several
SHR-NTD or AF1 domains using circular di-
chroism-, NMR-, Fourier transformed infra-
red-, and fluorescence emission- spectrosco-
pies and proteomic methods (135, 172–176).
Table 1 summarizes the secondary structure
content for different SHR-NTD and AF1 ac-
tivities under different experimental condi-
tions. From these studies, it can be concluded
that the NTD typically lack stable secondary
structure but have the propensity to form-he-
lical conformation. Interestingly, the AF1b re-
gionof theMR-NTDappears tobemore stably
folded than the rest of the domain and to have
predominantly -strand secondary structure (135). SHR-
NTDtherefore exist as an ensemble of conformationshav-
ing more or less stable secondary and tertiary structures
(Fig. 3).
It iswell known that the SHRAF1/NTDgenerallywork
in conjunction with other coregulatory proteins and by
multiple mechanisms (177–182). This raises the question:
what is the structural basis of the functional activity of the
IDNTD/AF1 in the context of full-length SHR action? As
discussed in Section III, studies carried out so far, includ-
ing analysis of the crystal structure of the full-length
PPAR and RXR (105), suggest that the AF1 may be
unstructured even in full-length receptor. Furthermore, in
the case of the GR, PR, and AR, the NTD is ID within the
context of a two-domain fragment containing the entire
NTD and DBD (174, 183, 184). It can be hypothesized
that one of the reasonswhy the holo-receptor is associated
with several chaperone proteins in the cytosol, before li-
gand binding, is protecting this large ID region from deg-
radation. However, available data indicate that all the
knownchaperone proteins bind to theLBDof the receptor
(see Section II.A), except in the case of the AR-NTD in-
teractions with the C terminus of the Hsp70-interacting
protein (246) and the co-chaperone protein Bag1L (185,
186). That raises another question: if these proteins bind
Figure 3.
Figure 3. ID proteins/domains exist as an ensemble of conformers, which collectively
appear to be unstructured. Each conformer is in a reversible equilibrium with each
other. Except for a very small fraction, which may be relatively well ordered (shown
in center), all other conformers possess the characteristics of random coil or molten
globule-like structures.
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to the LBD, how do they protect NTD structure? The
answer to this question may lie within the dynamic struc-
ture of the SHR protein that allows sensing of the intra-
cellular environment and efficient intramolecular domain
interactions, which in turn may induce structure in the
otherwise IDNTD. In fact, this hypothesis is supported by
the finding that certain chemical chaperones known to
protect/stabilize protein structure are capable of inducing
a compact structure in the AF1/NTD of the AR, GR, and
MR (135, 176, 187–190) (Table 1 and Fig. 4) and the
growing evidence for N/C-terminal interactions among
SHRs (see Section II.A.3). Because structural flexibility
has advantages for the assembly of large multiprotein
complexes, once the ligand-bound receptor enters the nu-
cleus, the NTD/AF1 may be again unstructured until it
encounters a specific binding partner(s) including site-spe-
cific DNA and/or coregulatory proteins.
Regulatory regions of many signaling proteins includ-
ing SHRs are known to form an assembly of protein com-
plexes ina rapidandwell-coordinatedmanner for efficient
and target-specific regulation of gene expression (49, 119,
120). It has been proposed that the ID nature of the NTD/
AF1 allows rapid and reversible adoption of various struc-
tural configurations controlled by allosteric modulations
through inter- and intramolecular communication and se-
lective responses to cellular environments. Because ID do-
mains (e.g., SHR-NTD/AF1) can exist as a large collection
of highly dynamic and rapidly interconverting conforma-
tions (Fig. 3), which may vary at a given time depending
upon cellular crowding under physiological conditions,
the ID nature of the NTD/AF1 allows it to rapidly sample
the cellular environment until partner binding proteins of
appropriate concentration and affinity are found. Then,
either by induced fit or selective binding of a particular
conformer, a high-affinity NTD/AF1:coregulatory pro-
tein interaction occurs (Fig. 4). During the course of gene
regulation, SHRs interact with various coregulatory pro-
teins, site-specific DNA, and small molecule steroid li-
gands (Fig. 1). These interactions occur at precisely de-
fined locations within the SHR protein, but their effects
are sometimes propagated to distal regions/domains, trig-
gering highly specific responses.
Generally, under physiological conditions, proteins
must have specific structure to carry out their proper func-
tions. The GR-AF1 domain was the first region of any
nuclear receptor to be characterized as being ID (172,
173). It was further reported that this ID region can be
induced to adopt a helical structure when incubated in the
presence of trifluoroethanol (TFE) (Table 1). At that time,
it was hypothesized that theGR-AF1might not require an
ordered conformation and act through the so-called “acid
blob” concept (172). However, several mutagenesis stud-
TABLE 1. Measured secondary structure in nuclear receptor NTD and or AF1 domains
Receptor Conditions
Secondary structure elements
Method Refs.-helix -strand -turn Bend Coil
AR-AF1 Buffer 13 20 32 36 CD 176
Buffer 16 24 17 19 24 FTIR 188
TFE 40 15 20 25 CD 176
TMAO 37 17 11 11 24 FTIR 188
 TFIIF 35 15 14 17 21 FTIR 188
AR-NTD Buffer 14 27 24 34 CD 242
TFE 58 12 9 22 CD 242
GR-AF1 Buffer 26.7 11.6 12.3 10 39.4 FTIR 243
Buffer 26 13 61 CD 180
 TBP 42.1 11.8 12.4 9.3 24.4 FTIR 243
P-serine 45 19 36 CD 180
MR-AF1a Buffer 11 29 25 36 CD 135
TFE 63 5 10 22 CD 135
MR-MD Buffer 13 22 24 40 CD 135
TFE 66 13 7 15 CD 135
MR-AF1b Buffer 19 32 31 19 CD 135
TFE 13 31 23 33 CD 135
MR-NTD Buffer 20 21 24 35 CD 135
TFE 79 2 3 15 CD 135
PR-AnDBD Buffer 30 CD 97
 JPD2 58 11 17 CD 97
EcR-NTD Buffer 8 31 23 89 CD 244
dHR38-NTD Buffer 11.1 11.7 10.3 66.6 CD 245
TFE 72.3 4.4 8.7 17.8 CD 245
JPD2, Jun-protein dimerization 2; P-serine, phosphorylated serine(s); TMAO, trimethylamine N oxide; EcR, ecdysone receptor; CD, circular dichroism; FTIR, Fourier
transform infrared spectroscopy.
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ies suggest that negative charges per se are not sufficient
for AF1 activity; indeed, key hydrophobic amino acids
may be crucial for AF1 activity (124, 125). The pattern of
proteolytic degradation products in cell-free extracts sug-
gested that the GR-AF1might be structured in vivo (126).
Furthermore, helix-destroying mutations of amino acids
in three hypothetical helices of the GR-AF1 strongly re-
duced GR transcriptional activity (172, 191). Thus, it
could be hypothesized that theGR-AF1may be structured
in vivo, at least when directly involved in transcriptional
activation. Subsequent studies with other SHRs such as
AR, PR, ER, and MR showed similar trends (135, 174–
176, 189). In recent years, it has been shown that the
NTD/AF1 of SHRs undergo coupled binding/folding
events. It has been well established that like many other
transcription factors, during transcription regulation the
NTD/AF1 shifts to a conformational space in whichmore
structured conformers exist (Table 1 and Fig. 4).
The crowded conditions inside the cell have been sug-
gested to cause ID proteins to fold into an ordered three-
dimensional structure. Molecular crowding in cells may
include small molecule solutes and macromolecules in-
cluding proteins, DNA, and RNA. Because SHRs are
known to function in a cell/tissue-specific manner and
AF1-mediated transcriptional activity is particularly sen-
sitive to cellular environment (see Section IV), it can be
hypothesized that one of the reasons for cell-specific ef-
fects of AF1 may be influenced by binding/folding events
governed by molecular crowding in specific cells. Several
mechanisms important in inducing ordered conforma-
tions of the NTD/AF1 under physiological conditions
have been described, which in turnmay facilitate receptor
interaction with specific coactivators and subsequent
transcriptional activity.
1. Role of small molecules (osmolytes)
Functionally folded structures of most macromole-
cules are sensitive to changes in cellular environmental
conditions. The native functional activities and stability
of macromolecules are fine-tuned through accumula-
tion of high concentrations of small organic molecules
known as osmolytes or chemical chaperones. Cells reg-
ulate many biological processes such as protein folding
and protein-protein interactions via accumulation of
Figure 4.
Figure 4. Folding of the SHR-NTD. The NTD exists has an ensemble of conformations, having more or less stable structure (middle molecule). A
more stably folded conformation of the NTD can be induced or selected by small molecules (osmolytes), posttranslational modification (e.g.,
phosphorylation), DNA binding, and interactions with coregulatory proteins. In these models of NTD folding, the more stable structure is shown to
be -helical by the solid cylinders (blue).
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specific osmolytes (190, 192–195). In recent years, the
mechanism of osmolyte compatibility and osmolyte-
induced stability has attracted considerable attention.
Osmolytes that occur naturally represent different
chemical classes such as amino acids (proline and gly-
cine),methylamines (betaine and trimethylamine-N-ox-
ide), andpolyols and sugars (sorbitol and trehalose) (190).
Because osmolytes predominantly affect the protein back-
bone, the balance between osmolyte-backbone interac-
tions and amino acid side chain-solvent interactions de-
termines protein folding (192–195). In ID proteins, the
hydrophobic amino acids are insufficient, relative to the
charged side chains, to cause spontaneous folding (156,
188, 205–207). Addition of the solvophobic effect of a
profoldingosmolyte can tip the energybalance in the favor
of folding because the backbone collapses to avoid solvent
interactionswith the osmolyte (192–195). The quantity of
osmolyte required depends on both its inherent solvopho-
bic properties in the interactionwith the peptide backbone
and the free energy balance provided by the sum of all
backbone-osmolyte interactions and the sum of all amino
acid side chain-solvent interactions (192–195).
The ID NTD of SHRs, or isolated AF1 regions, can be
induced to fold spontaneously to native, functional forms
by addition of certain organic osmolytes to the solvent
(135, 173, 176, 196, 197) (Table 1 and Fig. 4). Incubation
with several osmolytes causes the ID AF1 domain of the
GR to fold into a form that can bind strongly to specific
coregulatory proteins that are critical for the transcrip-
tional activity of the receptor (196). The folding curves
were cooperative and typical of a protein that folds spon-
taneously via the classic “two-state” model. This strongly
suggests that a natural conformation had been reached
(196). Osmolytes also reduced limited proteolysis of the
GR-AF1 polypeptide and resulted in the tryptophan and
tyrosine residues becoming less solvent exposed, which is
consistent with folding or increased conformational sta-
bility of the receptor domain (196). Similarly, the ID AF1
domain of the AR has been shown to have the propensity
to form helical structures in the presence of the osmolyte,
trimethylamineN-oxide (188), and toadopt amore folded
conformation that was resistant to limited proteolysis
(176, 189) (Table 1). Furthermore, this osmolyte-induced
conformation in the AR-AF1 domain significantly facili-
tates its interaction with a critical coregulatory protein
(188, 189). TrimethylamineN-oxide has also been shown
to stabilize a more folded conformation for regions of the
MR-NTD and, in the case of central 139 amino acids,
increase binding of a number of coactivator and corepres-
sor proteins (Table 1) (135).
Recent studies suggest that trehalose-induced folding
of the GR-NTD facilitates binding to a glucocorticoid re-
sponse element (GRE) in the context of a two-domain GR
polypeptide containing the entire NTD plus the DBD,
termedGR500 (190). It has been previously reported that
GR500 is capable of binding to GRE and can stimulate
AF1-mediated GR activity similar to that observed with
the hormone-bound full-length receptor. Taken together,
the above results suggest that osmolyte-induced folding
of the NTD or AF1 of SHRs may be important for the
interaction of the receptor protein with both coregulatory
proteins and response element DNA.
2. Binding of DNA and protein partners
According to the classic model of SHR action (Fig. 1),
receptor bound to specific hormone response element
(HRE) by virtue of high-affinity interactions modifies
chromatin structure and/or contacts the multiprotein
transcription machinery to regulate transcription from a
target promoter (59, 95, 119, 120, 230).
a. DNA architecture and SHR-NTD folding. In recent years, it
has become evident that SHR:HRE binding also influ-
ences the three-dimensional configuration of the receptor
(95). Consequently, in an HRE-specific manner, through
conformational rearrangements, the surfaces of the SHRs
aremodified such that various critical ancillary factors can
bind (95). Furthermore, DNA-binding can also be a trig-
ger for an active intramolecular communication that can
change the conformation of the SHRs in a site-specific
manner (199). Because transcriptional control of a specific
genedependsupon the interactions of the SHRwithDNA/
chromatin, the exact DNA sequences and architecture
of the response elements in the regulatory regions of the
gene could help determine the hormone response. Spe-
cific sequences within estrogen response element (ERE)
have been shown to modulate the conformation of ER
(200, 201), and conformational changes resulted in al-
tered recruitment of coactivator proteins to the ER:ERE
complex (199). This provides an intellectually satisfy-
ing rationale for the varied transcriptional effects of
specific sequences found in the SHR genomic binding
sites controlling specific genes. Furthermore, as dis-
cussed in Section III, recent HDX experiments demon-
strated that binding of DNA response elements led to
changes in the dimerization andAF2 surfaces of each part-
ner in a heterodimer receptor complex (138). However, it
also raises the question: what are the regions/domains of
the receptor that may be most prone to these conforma-
tional changes due to HRE binding? Several studies have
shown that dramatic folding effects have been seen on the
AF1/NTD of SHRs when DNA binding takes place (174,
183, 184, 201). Moderate conformational changes have
also been observed in other domains, namely, the DBD
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(95) and LBD (138), due to DBD:HRE interactions. Stud-
ies with theGRhave shown that stoichiometric binding to
a consensus GRE by the two-domain GR500 polypeptide
led to the formation of secondary/tertiary structure in the
NTD, suggesting that considerable binding energy may
have been devoted to intramolecular rearrangement in the
otherwise ID NTD (183). Similar studies on the two-do-
main PR fragment indicated that DNAbinding resulted in
the stabilization of structure in the ID NTD of both the A
and B forms of the receptor (174). It is important to note
here that when expressed as recombinant protein, even
in these two-domain fragments, the NTD remains
mostly unstructured until it binds to specific HRE se-
quences (183).
This interdomain communication also works in re-
verse. The presence of the NTDwas found to reduce the
binding affinity of AR-NTD-DBD relative to AR-DBD
alone (184). The NTD had to be covalently attached to
the DBD, supporting a role for intramolecular contacts,
and did not significantly change the protein-nucleotide
contacts.
Together, these results suggest that one of the reasons
why sequence specific DNA binding has such a profound
effect on the functionof SHRsmaybebecause the IDNTD
can gain a functionally active structure such that it can
bind appropriate coregulatory proteins when HRE:DBD
interactions occur. Consequently, coregulatory proteins
that bind to the SHRs are excluded or included in the
transcription complex by virtue of the receptor surfaces
available, which in turn are a consequence of site-specific
DNAbinding andDNAarchitecture (Fig. 4). Thus, part of
the functional structure of the SHR necessary for positive
regulation of transcription depends on receptor-DNA
binding. This structure may differ from the conformation
at genes negatively regulated by SHRs, where the receptor
is not necessarily bound to DNA—for example, receptor
interactions with other transcription factors to repress the
expression of target genes. At such sites, the SHR is teth-
ered toDNA indirectly via binding to a heterologous tran-
scription factor. For example, the effect of estrogen at the
pS2 gene is mediated through a cross talk between the ER,
ERE, and an activator protein 1 response element (202).
More extensive analyses are needed to reveal all the struc-
ture-function variations in the SHR and its NTD/AF1 in
order to understand receptor-mediated transcription in
various contexts.
b.CoregulatoryproteinbindingandSHR-NTDfolding.Several
coregulatory binding partner proteins are involved in the
action of the SHR on target gene transcription (49, 119,
203, 204). There are several examples in which binding
sites within the ID regions of many transcription factors
contain molecular recognition features, which consist of
short stretches of amino acid sequences that undergo a
disorder-to-order transition and are stabilized by binding
to a partner protein(s) that act as coregulators (153, 156,
188, 205–207). Thermodynamics predicts that if one or
more conformers of an ID protein/region bind specific
proteins with high affinity, interaction of the ID region
with that partner at appropriate concentrationsmay cause
its structure to stabilize (208, 209). It has been predicted
that these segmentsmay have advantages for cell signaling
by allowing the decoupling of partner binding specificity
and affinity, due to which the strength and duration of
signaling events can evolve (208, 209).
Coregulatory proteins are known tomodulate the tran-
scriptional activity of the SHRs through multiple mecha-
nisms. The SHR:coregulator complexes can act to modify
chromatin, influence RNA polymerase II phosphoryla-
tion, and bind mediators and proteins of the basal tran-
scription complex. Many of the known key SHR coregu-
lators bind to both the NTD/AF1 and AF2, using distinct
receptor binding sites (210–213). In recent years, the
mechanismof action and the structure of AF2:coregulator
interaction and its effects on the regulation of SHR target
genes have been explained in depth (5, 45, 46, 63, 231).
However, how the choice of AF1:coregulator interaction
is made and its functional significance in gene regulation
by SHRs remain poorly understood. There are examples
in which the ID regions of a transcription factor protein
take full shape upon interaction with protein binding
partner(s) through an induced-fitmodel of folding (154,
214). Based on this model, it has been hypothesized that
NTD/AF1 is not fully structured in vivo until it binds to
one or more coregulatory protein(s), and this induced
conformation or limited set of conformations in NTD/
AF1 is a prerequisite for its interaction with specific sets
of other coregulatory proteins in a cell- and promoter-
specific manner.
The NTD/AF1 of SHRs is known to recruit proteins
from the basal transcriptional machinery. For example,
the TATA box binding protein (TBP) can directly bind to
the NTD/AF1 domain of several SHRs (135, 175, 182),
and RAP74, a subunit of the transcription factor IIF
(TFIIF) complex, interacts with the ARAF1 domain (179,
215). Significantly, the TBP binding induces secondary/
tertiary structure formation in theGR-AF1 (182) (Table1)
and ER-NTD (175). Using several biophysical and par-
tial proteolytic digestion experiments, the GR-AF1 has
been shown to assume a three-dimensional fold with sig-
nificant helical content upon interaction with TBP (182).
The TBP binding-induced folding in the GR-AF1 signifi-
cantly enhances its interaction with SRC-1, and subse-
quent AF1-mediated, GRE-driven promoter-reporter ac-
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tivity (182). Similar studies have been reported for the
ER-NTD (175). TBP has a central role in the basal tran-
scription machinery, and it is interesting to note that it
directly binds to the NTD of the ER but failed to bind
ER-NTD (175). This difference in TBP binding implies
differential recruitment of target proteins by the NTD of
ER andER. The affinity of the ER andGR-AF1/NTD:
TBP interaction was determined to be in the micromolar
range, as assessed by surface plasmon resonance spectros-
copy (175, 182). Based on these results, it has been pro-
posed that the interaction between theAF1/NTDandTBP
may proceed in a two-step manner with initial very fast,
low-affinity association, followed by a slow, folding event
and tighter association (175, 182). The initial association
may occur by electrostatic interactions between the acidic
residues of highly negatively charged AF1/NTD and the
positively charged TBP. However, this initial unstable
protein complex subsequently may convert into a more
stable form by the folding of the ID AF1/NTD and the
formation of specific contacts between the two proteins
(216–218).
Furthermore, the dissociation of this binding interac-
tion suggested a complex behavior, with a rapid dissoci-
ation forAF1/NTDmolecules that didnot undergoproper
folding and a slower dissociation for those molecules that
did fold successfully upon physical interaction with the
TBP (175). Such a two-step binding mechanism is consis-
tent with the change in protein conformation that accom-
panies the AF1/NTD:TBP interaction. Based on the bind-
ing and consequent folding of the AF1/NTD, it can be
hypothesized that the interaction between SHR-NTD/
AF1 domains and protein(s) from basal transcription ma-
chinerymay be a unifiedmechanism, throughwhich these
ID AF1/NTD acquire a functionally active conformation
under physiological conditions. In this conformation, the
NTD/AF1 may be able to create favorable protein inter-
action surfaces for binding with other coregulatory pro-
teins. The exclusion of certain other binding partners can-
not be ruled out. It could thus be hypothesized that a
complex and dynamic binding pattern for the NTD of
SHRs occurs to achieve transcriptional activation, where
the NTD/AF1 regionmust be able to obtain different con-
formations dependent on the binding partner(s) (Fig. 4).
Induced folding of the AR-AF1 domain due to its inter-
action with RAP74 and facilitation of its interaction with
SRC-1 lends further support to this hypothesis (176, 188,
189). Together, these results may provide a potential
mechanism through which SHR AF1 domains may regu-
late the expression of specific genes, information essential
to an understanding of how the hormone signals are
passed from the receptor to target genes. However, a
clearer picture will likely emerge when the functionally
folded three-dimensional structures of the NTD/AF1
bound to different coregulatory proteins are solved and
can be compared.
In addition toDNAbinding anddimerization, theDBD
has also been highlighted as a site for protein-protein in-
teractions and may act as a hub for the transmission of
allosteric signals as a result of receptor binding of both
hormone andDNA. Significantly, binding of coregulatory
proteins to the PR-DBD CTE has been described, which
results in allosteric regulation and folding of the PR-NTD
(97, 106, 219) (Table 1).
3. Posttranslational modifications and SHR-NTD folding
Posttranslational modification is an important phe-
nomenon that controls the functions of transcription
factors in cells by regulating their DNA-binding affin-
ity, interaction with components of the transcription
initiation complex, and the shuttling between the cel-
lular compartments (220). The SHRs are the target for
a plethora of posttranslational modifications, including
phosphorylation, acetylation, methylation, and sumoy-
lation, and thesemodifications have a complex effect on
SHR signaling (221). In some cases, one type of post-
translational modification can influence another type
(198, 222). Acetylation of the lysine residues in the AR
hinge domain plays an important role in AR-mediated
gene regulation, and mutation of these residues can im-
pair phosphorylation of serine 94 in the NTD (103,
198). Similarly, methylation of these residues enhances
AR-dependent transactivation by increasing N/C-ter-
minal interactions and recruitment of the receptor to
target genes (104, 223). The interplay of phosphoryla-
tion and sumoylation in the regulation of ERR-NTD
transcriptional activity has also been observed, and
these modifications form a conserved phosphosumoyl
switch that exists within a larger synergy control motif
(224).
Recent studies have suggested that signaling via phos-
phorylation-regulated protein-protein interaction often
involves ID regions, and these regions have a much higher
frequency of known phosphorylation sites than ordered
regions, suggesting a strong preference for locating phos-
phorylation sites in the ID regions (153). One of the main
reasons for such propensity is to facilitate extensive for-
mation of hydrogen bonding between the backbones
and/or side chains that can occur through disorder-order
transition within the ID region. The formation of these
hydrogen bonds would be difficult if the sites of phos-
phorylation were located within ordered regions (153,
209). In terms of structural consequences of site-specific
phosphorylation, both disorder-to-order and order-to-
disorder conformational transitions have been ob-
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served to follow the phosphorylation event, and these
conformational changes often affect protein function
(153). Lack of well-defined structure is generally asso-
ciatedwith specific sites of enzyme-catalyzed phosphor-
ylation and ubiquitination sites (209), which facilitates
the inclusion or exclusion of specific binding partners in
the complex (209). Because a significant part of the
binding energy is required to fold an ID region, high
specificity coupled with low affinity provides the basis
for easily reversible interactions (209).
Like many other transcription factors, the SHRs are
phosphoproteins, and it has been suggested that kinase-
mediated phosphorylation plays an important role in the
regulation of their activities (225). Phosphorylation of
specific residues within the NTD/AF1 of the GR and ER
regulates the transcriptional activity of these receptors
(226–228). There are also reports suggesting that phos-
phorylationmay affect SHR stability and thus alter recep-
tor activity (180). Analysis of known phosphorylated res-
idues within the AR-, ER-, GR-, and PR-NTD with
predicted ID reveals a strong correlation (Table 2). In the
case of the ER and the GR, site-specific phosphorylation
hasbeenassociatedwith conformational changes in the ID
AF1 region (180, 229). Based on a simulation modeling
approach, it was proposed that phosphorylation of serine
211 in the human GR-AF1 may result in the formation of
more compact structure in the surrounding peptidewithin
the AF1 (amino acids 187–244), which may expose novel
protein surface for cofactor interaction (228). Further-
more, it was shown that common surfaces within GR af-
fected by phosphorylation may be responsible for influ-
encing the regulation of selective genes (228).More recent
studies show that when GR-AF1 is phosphorylated at ser-
ine 211, using the p38 MAPK, secondary/tertiary struc-
ture is formed in theAF1domain (Table1), suggesting that
under physiological conditions, site-specific phosphory-
lation may play a crucial role in allowing the ID AF1 do-
main of the GR to adopt functionally active conforma-
tion(s) (180). Furthermore, it was found that the resulting
structurallymodified forms ofAF1 facilitated interactions
with critical coregulatory proteins (CBP, TBP, and SRC-
1), and possibly additional factors, resulting in the assem-
bly of multiprotein complexes involved in GR-mediated
regulation of transcription (180).
These findings demonstrate a mechanism through
which the ID NTD of SHRs may adopt a functionally
active conformation under physiological conditions in re-
sponse to phosphorylation.More generally, it can be con-
cluded that the SHR-NTD may be structured in vivo, at
least when phosphorylated and/or directly involved in in-
teractionswithDNAandbindingpartnerproteins (Fig. 4).
VI. Intrinsic Disorder Can Optimize
Allosteric Coupling
Allosteric coupling is a common phenomenon associated
with proteins with modular structures (230) and can be
defined by propagation of conformational perturbation in
one domain/region of the protein due to signals passed
from distant sites in the same molecule. As discussed
above, due to their modular structures and regulation
through specific ligands interacting with different do-
mains (i.e., coregulatoryproteins forNTDandLBD,DNA
for DBD, and steroid hormone for LBD), SHRs are tightly
regulated through allosteric coupling (230, 231). Each of
these interactions can act as signals that modulate inter-
actions with other molecules and/or establish intramolec-
ular and interdomain communications (Fig. 5).As a result,
SHRs can switch from one functional state to another by
selective stabilization of different conformations, and the
ID NTD/AF1 may be the region that undergoes most sig-
TABLE 2. Location of known phosphorylated residues
in regions of predicted intrinsic disorder
Receptor Residue
Predictor of intrinsic disorder
PONDR RONN GlobPlot Fold index
AR-NTD S16 D D D
S81 D D D D
S94 D D D D
S210 D D D D
S256 D Border
S308 D D
S424 D D D
S515
ER-NTD S106 D D D
S118 D Border D
S167 D D Border D
GR-NTD S134 D D D Border
S203 D D D D
S211 D D D D
S226 D
S404 D D D
PR-NTD S20 D D D
S25 D D D
S81 D D D
S102 D D D Border
S130 D D D
S162 D D
S190 D D
S213 D D Border D
S294 D (Border) D
S345 D D D D
S400 D D
T430 D D D
S554 D D D
D, Intrinsic disorder; Border, residue is at the border of region of predicted
intrinsic disorder. ID was predicted from the primary amino acid sequences using
the algorithms PONDR (247), RONN (248), GlobPlot (249), and fold index (250).
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nificant structural rearrangement and so plays the major
role in the transmission of information to distal sites.
In the above description (Fig. 5) allosteric coupling is
proposed to induce an ordered conformation in the ID
domain through domain-domain interactions, and struc-
ture formation in these ID domains/regions is linked to
ligand binding either in the ID domain itself or in other
domains of the molecule. Thus, the disorder/order tran-
sition is coupled to long-range allosteric communication
within themolecule and is therefore important for its func-
tion (232). Significantly, it has recently been argued that
an additional functional consequence of ID is tomaximize
allosteric interactions (232). This has led to a new model
whereby allosteric coupling does not necessarily require a
conformational link between the two sites, but is rather a
consequence of the “energetic balance” and overall sta-
bility of the protein (232). In this manner, SHRs sample
various conformations and are primed to respond to
changes in different intracellular compartments. It is in-
teresting therefore that the removal of the NTD-flanking
sequences on both sides of theGR-AF1, by deleting amino
acids, that produces a peptide with AF1 immediately up-
stream from the DBD leads to acquisition of an ordered
conformation inAF1. In this construct, interaction ofAF1
with CBP/p300, but not SRC-1, is significantly increased
and concomitantly, theGRE-mediatedAF1activity (233).
Thus, proximity to the DBD or loss of flanking sequences
enhances certain folding properties of AF1 and subse-
quent activity, suggesting that these flanking sequences
play an inhibitory role in regulatingGR-AF1 structure and
activity (233). Unlike, the two-domain GR fragment
(GR500), binding of this peptide to a GRE fails to induce
any further structure formation in AF1 (233). These po-
sition-specific structural effects suggest that AF1 structure
(or propensity for structure formation) is strongly influ-
enced by the amino acids that surround it as well as by
influences from the DBD:GRE interaction. Strikingly,
these findings also support the process of allosteric cou-
pling through an intrinsic disorder mechanism, and the
NTD amino acid sequences that flank AF1must influence
these signaling processes (232). These results also provide
a mechanistic explanation for why certain N-terminally
Figure 5.
Figure 5. Interdomain communication and allosteric regulator of SHRs. Various inter- and intramolecular events may allosterically regulate the
structure and functions of the ID NTD/AF1 domain. Arrows indicate the flow of signals from one region/domain to another, throughout the SHR
protein. For example, binding of different SRM in the ligand binding pocket can pass the signal to the surface of the LBD and dynamically reorient
AF2 conformation and other parts of the domain. Signals are then passed to the hinge region, resulting in conformational rearrangements in the
hinge, transferring to the DBD and eventually to ID NTD/AF1. In a similar fashion, HRE-DBD binding passes signals to influence the structure of
NTD/AF1 and/or the AF2 surface. Direct binding of a coregulatory protein to NTD/AF1, site-specific phosphorylation, and possibly other
posttranslational modifications, and even ID NTD/AF1 flanking sequences within the NTD can be avenues for allosteric coupling involving ID AF1
and other receptor domains.
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truncated GR, and possibly other SHRs, splice variants
differ in their activities (10).
Allosteric mechanisms have evolved inmany transcrip-
tion factor proteins, and this flexibilitymay allowSHRs to
mediate diverse genetic responses directly by modifying
their malleable surfaces for specific interactions. Identifi-
cation of different ligand binding events and subsequent
allosteric coupling is likely to play an important role in
understanding the diverse target function of SHRs and
could be critical in developing improved therapeutic in-
terventions in several pathological conditions associated
with SHRs. In cells, SHR function in a very dynamic fash-
ion, existing as an ensemble of conformations that can
sample the cellular environment in a rapid manner, and
subsets of these conformations can be selected and stabi-
lized by hormone and DNA binding.
VII. Structural Dynamics and the Design of
Selective Small Molecule Modulators of
Steroid Hormone Receptor Function
It is generally accepted that receptor function is dependent
upon ligand-induced conformational changes (i.e., helix
12 orientation), together with the cellular complement
and levels of coregulatoryproteins.Asdiscussed in Section
V, it seems certain that the DNA architecture of receptor
binding sites and the folding of the AF1/NTDdomainwill
also contribute to cell-specific receptor actions. SHRs are
well-validated drug targets and are prognostic indicators
in a number of pathophysiological conditions, including
inflammation,hormone-dependent cancers, osteoporosis,
and cardiovascular disease (see Section I). Classical an-
tagonists of SHRs act as competitive inhibitors of the nat-
ural hormone by binding to the ligand binding pocket and
inducing a conformation that is unable to bind coactivator
proteins, or retains the receptor complex in the cytosol,
and/or targets the receptor for degradation. However,
there is increasing interest in the development and char-
acterization of compounds that exhibit mixed agonist/an-
tagonist properties depending on the cellular context;
these are best described as “selective receptor modulators.”
The “Holy Grail” for hormone therapies is to be able to
target SHR signaling in a receptor- and tissue-selectiveman-
ner to maximize therapeutic benefits and to minimize dele-
terious outcomes in other receptor target tissues.
The general problem with traditional antagonists or
SRMs is the development of resistance and/or off-target
side effects. It therefore makes sense to investigate the
possibility of identifying inhibitors that act outside of
the ligand binding pocket, which could complement or
replace existing SRMs. A number of groups have
screened different classes of molecules (natural prod-
ucts, biologics, or synthetic compounds) for such in-
hibitors, and a number of exciting and surprising out-
comes have been reported. For example, there are
several examples where SRM binding influences the
conformation of the receptor (234, 235), and these con-
formational changes collectively determine the specific
biological activity. Thus, a number of peptide probes
that recognize different conformations of a SHR bound
to different ligands have been identified. Although these
peptide libraries have proved their worth in character-
izing ligand-binding profiles, initially for the ER and
ER, they also open the possibility for developing se-
lective receptor peptide inhibitors (for example, Refs.
236–238) that will selectively disrupt receptor-SRM-
coregulatory protein complexes in a tissue-specific
manner.
The potential for allosteric inhibitors of receptor func-
tionwas emphasized by the finding that a number of small
molecules (e.g., flufenamic acid, 3,3,5-triiodothyroacetic
acid) disruptedprotein-protein interactions involvingAR-
AF2 and inhibited AR-dependent transactivation (74).
The surprise came when x-ray structures revealed these
molecules bound to a hydrophobic surface of the LBD,
termed BF3 (involving residues in helix 1, helices 3 to 5, a
loop, and helix 9), which is distinct from the ligand bind-
ingpocket, and crucially theAF2 region (74).This finding,
together with the information from peptide binding stud-
ies, suggests that other surfacesof theLBDmayparticipate
in protein-protein interactions and could therefore be
novel drug targets. Allosteric regulation could also stabi-
lize a specific conformer that reduces the affinity of the
second binding site for its ligand, and this dynamic could
be explored as a novel approach to structure-based SRM
design to produce differential responses.
In a separate study, a number of hits were identified
from a screen of two small-molecule libraries that inhib-
ited ER-dependent DNAbinding (239). One of thesemol-
ecules, theophylline,8-[(benzylthio)methyl]-(7Cl,8Cl), se-
lectively inhibitedER-dependent transcription and acted
outside of the ligand binding pocket. Similarly, two com-
pounds, pyrvinium pamoate and a natural product, har-
mol hydrochloride, have been described that inhibit AR
activity, independent of hormone binding (240). Harmol
appeared to disrupt DNA binding, whereas pyrvinium
acted at a subsequent step in receptor signaling, possibly
disrupting protein-protein interactions (240). Although
the binding sites on theERorAR for these smallmolecules
have yet to be identified, they illustrate the possibilities for
developing inhibitors that target other domains of SHRs.
The structural flexibility of the SHR-AF1/NTD may
have appeared to be a rather unattractive target for small-
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molecule inhibitors of receptor function. However, the
uniqueness and functional importance of the NTDmakes
it a worthwhile, even if technically challenging, drug tar-
get. It is therefore highly significant that a small molecule,
identified in a screenof compounds isolated fromamarine
sponge, was recently shown to be highly effective and spe-
cific at inhibiting AR activity in vitro and in vivo (241).
The compound, termed EPI-001, is a bisphenol A ester
derivative (BADGE), and it interacted with the AR-AF1
domain, differentially disrupted protein-protein interac-
tions, and reduced binding to androgen-regulated genes
(241). Overall, this study provides “proof-of-principle”
that small-molecule inhibitors can be identified that target
the structurally plastic SHR-NTD.
Traditionally, it has been difficult to design or iden-
tify small molecules that target protein-protein inter-
faces, given the hydrophobic nature and relatively large
surface area of such sites. However, the above-men-
tioned studies would challenge this preconception and
open up the potential to develop tissue-specific modu-
lators of SHR action that would complement or replace
exiting therapeutics.
VIII. Conclusions and Future Challenges
The last 25 yr have seen tremendous progress in our un-
derstanding of the structure-function relationships of
members of the nuclear receptor superfamily, including
SHRs. This has included the isolation of receptor cDNA;
the solving, at atomic resolution, of the structures of the
isolated DBD and LBD; the identification of binding part-
ners; and a clearer appreciation of the role of ID and al-
losteric coupling in receptor action. The future will prove
to be just as challenging and exciting, and we may rea-
sonably expect progress in a number of areas.
Solving the three-dimensional structure of a full-length
SHR has proved a major technical challenge. However,
our increased understanding of the functional and struc-
tural properties of the IDNTD, togetherwith the allosteric
coupling through hormone and DNA binding, opens up
the possibility of investigating the conformationof a SHR-
DNA-coregulatory protein(s) complex. In the absence of
a structure for a full-length SHR complex, it will be im-
portant at the very least to obtain structural information,
perhaps through small angle x-rays or DHX experiments,
for a two-domain SHR in the presence and absence of
DNAbinding site andproteinbindingpartners. Such stud-
ies will be invaluable if we are to further understand the
structural basis for SHR-dependent gene regulation and
allosteric control. Such information will also be vital to
our understanding of the impact of point mutations in
receptor-dependent diseases and in the design of novel
inhibitors and SRM ligands to modulate tissue-specific
SHR action.
In conclusion, SHRs are highly modular proteins,
and this property has been exploited in the regulation of
these molecules by the binding of different ligands (hor-
mone, DNA, coregulatory proteins). The result is the
exquisite control of normal physiology by steroid hor-
mones and the serious consequences that arise through
misregulation in the pathophysiology of certain can-
cers, inflammatory disease, and cardiovascular disor-
ders. It has become increasingly clear that the NTD,
containing the major transactivation function AF1, is
naturally ID, and that this structural plasticity is func-
tionally important for SHR activity. The SHR-NTD ex-
ists as an ensemble of conformers, having more or less
structure, which prime this region of the receptor to
rapidly respond to changes in the intracellular environ-
ment through hormone binding and posttranslation
modifications. It is interesting that the NTD itself is
often highly modular, with multiple regions contribut-
ing to receptor-dependent gene regulation. This seems
particularly the case for the SHRswith the largest NTD:
AR, PR, and MR. The consequences of this are unclear
at present, but it may be significant that the length of the
NTD has been correlated with AF1 “strength” in a re-
porter gene assay. A picture is emerging where the in-
duced folding and/or stabilization of a functional con-
formation in the NTD is achieved through coregulatory
protein binding and/or allosteric couplingwith theDBD
and DNA response element binding, and we are begin-
ning to understand how different surfaces within the
SHR protein may be created and used to control target
gene expression.
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